India Globalization Capital, Inc. (IGC) is engaged in the development of cannabinoid-based therapies for indications such as Alzheimer's disease and pain. IGC operates through two segments: Life Sciences and Infrastructure. Life Sciences segment includes the development of potential new drugs, hand sanitizers and several hemp-based Cannabidiol (CBD) products and brands, wholesale of hemp extracts, including hemp crude extract and hemp isolate, white labeling of hemp-based products, and offering of tolling services like extraction and distillation to hemp farmers. Infrastructure segment includes construction contracts, rental of heavy construction equipment and purchase and resale of physical commodities used in infrastructure. IGC'S Life Sciences brands include Hyalolex, Holi Hemp, Holief, Herbo, and Sunday Seltzer. It is also focused on developing Naphthalene Monoimide (NMI) lead candidate, IGC-AD1, that targets neuropsychiatric symptoms associated with dementia in Alzheimerâ€™s.
Number of employees : 52 people.
|Life Sciences||0.72||80.5%||0.36||90.7%|| -50.35%|
|USD in Million
|USD in Million
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Ram Mukunda ||4,052,178||
|Global X Management Co. LLC ||1,127,270||
|Richard K. Prins ||755,000||
|BlackRock Fund Advisors ||706,242||
|The Vanguard Group, Inc. ||629,478||
|Claudia Grimaldi ||558,821||
|Carroll Financial Associates, Inc. ||320,000||
|Geode Capital Management LLC ||302,884||
|John E. Lynch ||284,401||
|Virtu Americas LLC ||281,304||
Sector Commercial Equipment Rental
Connections : India Globalization Capital, Inc.